ArticleFrontiers in oncology2025
LAT1 expression in head and neck cancer: a prognostic biomarker with potential relevance for BNCT.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Boron-embedded multifunctional nanoplatform toward potential combined boron neutron capture therapy and immunomodulation in glioma.Smart molecules : open access · 2026Article
- Review
- ERα36 is associated with SLC7A5/LAT1 expression, cervical cancer progression, and BNCT response: a translational study.Frontiers in oncology · 2026Article
- Commentary: LAT1 expression in head and neck cancer: a prognostic biomarker with potential relevance for BNCT.Frontiers in oncology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The increased expression of LAT1, an amino acid transporter, in cancer cells makes boronophenylalanine (BPA) uptake higher in cancer Methods: We analyzed 100 HNSCC patients treated with multimodal treatments including radiotherapy. Transcriptomics of primary tumor specimens was obtained by Affymetrix ClariomD chips and processed using the Transcriptome Analysis Console Software (ThermoFisher). We retrieved normalized and log2 LAT1 from the data matrix. Data were used to analyze: i) the distribution by anatomical subsites and transcriptomic subtypes (assessed by Kruskal-Wallis test); ii) overall survival (OS). Results: LAT1 expression was high (>2.83) in 13% of cases. At median follow-up of 64.44 months (95% CI: 54.24-66.91), overall median OS was 94.24 months, 22.99 months (95% CI 14.31-NR) in patients with high LAT1 Conclusion: High LAT1 expression has a negative prognostic role and is associated with transcriptomic clusters with unfavorable and radioresistant biologic features. These results justify the use of BNCT in radioresistant HNSCCs and may guide patient selection for future clinical studies with BNCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.